|
Re: variation of the mutation between ER+ and ER- in Her2+
Sorry for the delay in replying yes indeed I agree with all the former comments. the hormonal status indicates a difference in the co-mutation (beside Her2+) of the two groups.
Indeed Hopeful is right that this variation should indicates that different approaches apply when the aim of the treatment is to block over express receptors. It seems that generally for ER neg one the embryo-genesis process is swith on via the Wnt pathway. Off course, things are still not clear cut just like they have now discovered that the her2+ can be p95Her2 (not responding to herceptin) but responding to TK..
__________________
35 y/o
June 06: BC stage I
Grade 3; ER/PR neg
Her-2+++; lumpectomies
Aug 06: Stage IV
liver mets: 6 tumours
July 06 to Jan 07: 2*FEC+6*Taxotere; 3*TACE; LITT
March 07- Sept 07: Vaccination trial (phase 2, peptide based) at the UW (Seattle).
Herceptin since 2006
NED til Oct 09
Recurrence Oct 2009: to internal mammary gland since October 2009 missed on Oct and March 2010 scan.. palpable nodes in May 2010 when I realised..
Nov 2011:7 mets to lungs progressing fast failed hercp/tykerb/xeloda combo..
superior vena cava blocked: stent but face remains puffy
April 2012: Teresa Trial, randomised to TDM1
Nov 2012 progressing on TDM1
Dec 2012 blockage of my airways by tumours, obliteration of these blocking tumours breathing better but hoping for more- at mo too many tumours to count in the lungs and nodes.
Dec 2012 Starting new trial S-222611 phase 1b dual egfr her2+ inhibitor.
'Under no circumstances should you lose hope..' Dalai Lama
|